Role of multidetector computed tomography in the diagnosis and management of patients attending the rapid access chest pain clinic, the Scottish computed tomography of the heart (SCOT-HEART) trial: study protocol for randomized controlled trial by Newby, D.E. et al.
  
 
 
 
 
Newby, D.E., Williams, M.C., Flapan, A.D., Forbes, J.F., Hargreaves, A.D., 
Leslie, S.J., Lewis, S.C., McKillop, G., McLean, S., Reid, J.H., Sprat, J.C., 
Uren, N.G., van Beek, E.J., Boon, N.A., Clark, L., Craig, P., Flather, M.D., 
McCormack, C., Roditi, G., Timmis, A.D., Krishan, A., Donaldson, G., 
Fotheringham, M., Hall, F.J., Neary, P., Cram, L., Perkins, S., Taylor, F., 
Eteiba, H., Rae, A.P., Robb, K., Barrie, D., Bissett, K., Dawson, A., 
Dundas, S., Fogarty, Y., Ramkumar, P.G., Houston, G.J., Letham, D., 
O’Neill, L., Pringle, S.D., Ritchie, V., Sudarshan, T., Weir-McCall, J., 
Cormack, A., Findlay, I.N., Hood, S., Murphy, C., Peat, E., Allen, B., Baird, 
A., Bertram, D., Brian, D., Cowan, A., Cruden, N.L., Dweck, M.R., Flint, 
L., Fyfe, S., Keanie, C., MacGillivray, T.J., Maclachlan, D.S., MacLeod, 
M., Mirsadraee, S., Morrison, A., Mills, N.L., Minns, F.C., Phillips, A., 
Queripel, L.J., Weir, N.W., Bett, F., Divers, F., Fairley, K., Jacob, A.J., 
Keegan, E., White, T., Gemmill, J., Henry, M., McGowan, J., Dinnel, L., 
Francis, C.M., Sandeman, D., Yerramasu, A., Berry, C., Boylan, H., Brown, 
A., Duffy, K., Frood, A., Johnstone, J., Lanaghan, K., MacDuff, R., 
MacLeod, M., McGlynn, D., McMillan, N., Murdoch, L., Noble, C., 
Paterson, V., Steedman, T., and Tzemos, N. (2012) Role of multidetector 
computed tomography in the diagnosis and management of patients 
attending the rapid access chest pain clinic, the Scottish computed 
tomography of the heart (SCOT-HEART) trial: study protocol for 
randomized controlled trial. Trials, 13 (184). ISSN 1745-6215 
 
Copyright © 2012 The Authors 
 
 
 
http://eprints.gla.ac.uk/82149/ 
 
 
 
 
Deposited on:  9 July 2013 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Role of multidetector computed tomography in the
diagnosis and management of patients attending
the rapid access chest pain clinic, The Scottish
computed tomography of the heart (SCOT-HEART)
trial: study protocol for randomized controlled trial
Newby et al.
Newby et al. Trials 2012, 13:184
http://www.trialsjournal.com/content/13/1/184
TRIALS
Newby et al. Trials 2012, 13:184
http://www.trialsjournal.com/content/13/1/184STUDY PROTOCOL Open AccessRole of multidetector computed tomography in the
diagnosis and management of patients attending
the rapid access chest pain clinic, The Scottish
computed tomography of the heart (SCOT-HEART)
trial: study protocol for randomized controlled trial
David E Newby1, Michelle C Williams1*, Andrew D Flapan2, John F Forbes3, Allister D Hargreaves4,
Stephen J Leslie5, Steff C Lewis6, Graham McKillop2, Scott McLean7, John H Reid8, James C Sprat4, Neal G Uren2,
Edwin J van Beek9, Nicholas A Boon1, Liz Clark10, Peter Craig11, Marcus D Flather12, Chiara McCormack6,
Giles Roditi13,14, Adam D Timmis15, Ashma Krishan6, Gillian Donaldson8, Marlene Fotheringham8, Fiona J Hall8,
Paul Neary8, Louisa Cram4, Sarah Perkins4, Fiona Taylor4, Hany Eteiba13, Alan P Rae13, Kate Robb13, Dawn Barrie16,
Kim Bissett16, Adelle Dawson16, Scot Dundas16, Yvonne Fogarty16, Prasad Guntur Ramkumar16, Graeme J Houston16,
Deborah Letham16, Linda O’Neill16, Stuart D Pringle16, Valerie Ritchie16, Thiru Sudarshan16, Jonathan Weir-McCall16,
Alistair Cormack17, Iain N Findlay17, Stuart Hood17, Clare Murphy17, Eileen Peat17, Barbara Allen9, Andrew Baird9,
Danielle Bertram9, David Brian9, Amy Cowan9, Nicholas L Cruden2, Marc R Dweck1, Laura Flint2, Samantha Fyfe9,
Collette Keanie2, Tom J MacGillivray9, David S Maclachlan1, Margaret MacLeod2, Saeed Mirsadraee9, Avril Morrison2,18,
Nicholas L Mills1, Fiona C Minns2, Alyson Phillips2, Laura J Queripel9, Nicholas W Weir2,9, Fiona Bett19, Frances Divers19,
Katie Fairley19, Ashok J Jacob19, Edith Keegan19, Tricia White19, John Gemmill20, Margo Henry20, James McGowan20,
Lorraine Dinnel21, C Mark Francis21, Dennis Sandeman21, Ajay Yerramasu21, Colin Berry14, Heather Boylan14,
Ammani Brown14, Karen Duffy14, Alison Frood14, Janet Johnstone14, Kirsten Lanaghan14, Ross MacDuff14,
Martin MacLeod14, Deborah McGlynn14, Nigel McMillan14, Laura Murdoch14, Colin Noble14, Victoria Paterson14,
Tracey Steedman14 and Nikolaos Tzemos14Abstract
Background: Rapid access chest pain clinics have facilitated the early diagnosis and treatment of patients with
coronary heart disease and angina. Despite this important service provision, coronary heart disease continues to be
under-diagnosed and many patients are left untreated and at risk. Recent advances in imaging technology have
now led to the widespread use of noninvasive computed tomography, which can be used to measure coronary
artery calcium scores and perform coronary angiography in one examination. However, this technology has not
been robustly evaluated in its application to the clinic.
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Methods/design: The SCOT-HEART study is an open parallel group prospective multicentre randomized controlled
trial of 4,138 patients attending the rapid access chest pain clinic for evaluation of suspected cardiac chest pain.
Following clinical consultation, participants will be approached and randomized 1:1 to receive standard care or
standard care plus ≥64-multidetector computed tomography coronary angiography and coronary calcium score.
Randomization will be conducted using a web-based system to ensure allocation concealment and will incorporate
minimization. The primary endpoint of the study will be the proportion of patients diagnosed with angina pectoris
secondary to coronary heart disease at 6 weeks. Secondary endpoints will include the assessment of subsequent
symptoms, diagnosis, investigation and treatment. In addition, long-term health outcomes, safety endpoints, such
as radiation dose, and health economic endpoints will be assessed. Assuming a clinic rate of 27.0% for the
diagnosis of angina pectoris due to coronary heart disease, we will need to recruit 2,069 patients per group to
detect an absolute increase of 4.0% in the rate of diagnosis at 80% power and a two-sided P value of 0.05. The
SCOT-HEART study is currently recruiting participants and expects to report in 2014.
Discussion: This is the first study to look at the implementation of computed tomography in the patient care
pathway that is outcome focused. This study will have major implications for the management of patients with
cardiovascular disease.
Trial registration: ClinicalTrials.gov Identifier: NCT01149590
Keywords: Computed tomography, Coronary heart disease, Rapid access chest pain clinicBackground
The clinical presentation of chest pain is a major prob-
lem for primary health care professionals and is the
commonest medical reason for a patient attending the
Emergency Department. Ascertaining the aetiology of
the chest pain is essential not only for the future ma-
nagement and investigation of the patient, but also for
health care resources to be utilized appropriately and
efficiently. The distinction between cardiac and noncar-
diac chest pain can be subtle, leading, in some series
[1,2], to between 2 and 12% of patients being inappro-
priately discharged from hospital and more than 25%
being readmitted to hospital with benign noncardiac
chest pain. From the primary care perspective, Emergency
Department attendances or short-term hospitalizations with
an unhelpful diagnosis, such as ‘chest pain - myocardial in-
farction excluded’, do not provide a clear diagnosis or
management plan.Rapid access chest pain clinics
The accurate identification of patients with ischaemic
heart disease is important because up to 30% of patients
presenting with recent-onset angina have a cardiac event
within 1 to 2 years [3] and many of these patients may
benefit from coronary revascularization [4]. This has led
many centres to develop the provision of a rapid access
chest pain clinic. This out-patient clinic provides a ‘one-
stop’ assessment for patients with suspected angina, in-
cluding medical history, examination, electrocardiogram,
blood tests, and exercise testing where appropriate. It
does not include patients with acute chest pain who re-
quire immediate hospital assessment for suspected acutecoronary syndrome. We have demonstrated that such ser-
vices reduce the hospitalization of patients with benign
noncardiac chest pain whilst facilitating the identification
of those patients with acute coronary syndromes requi-
ring in-patient care [5]. A specialist cardiology opinion
combined with the resources of a chest pain clinic service
would appear to have a higher diagnostic yield for ischae-
mic heart disease than open-access exercise electrocar-
diography, and would provide the primary care physician
with a firm clinical diagnosis in the majority of cases,
and identify those patients requiring further invasive
investigation [5].The need for better diagnostic accuracy and risk
stratification
Rapid access chest pain clinics have now become estab-
lished across the United Kingdom and they have proven
successful in identifying high-risk patients with coronary
heart disease [6]. However, there is room for improve-
ment, with some patients continuing to be misdiagnosed
with noncardiac chest pain [6]. Moreover, those diag-
nosed with noncardiac chest pain account for up to a
third of patients who subsequently die from cardiovascu-
lar disease or suffer an acute coronary syndrome over 5
years of follow-up [6]. There is, therefore, a need for
better diagnostic accuracy and risk stratification in
patients attending rapid access chest pain clinics, espe-
cially in younger patients (<65 years) [7].Coronary artery calcification
Coronary artery calcification is an independent risk fac-
tor for coronary heart disease, with even low coronary
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The relative risk associated with coronary calcification is
greater than that associated with established factors,
such as smoking, hypertension and diabetes mellitus.
The progression of coronary artery calcification is asso-
ciated with a higher incidence of coronary events, even
in those people who are asymptomatic at the time of ini-
tial scanning [9]. Thus, the presence of coronary artery
calcification is not only indicative of atheromatous
plaque disease, but its progression may correspond with
cardiovascular event rates.
The degree of calcification correlates with atherosclerotic
burden but it does not identify soft plaque and may not
predict the patient’s response to medical interventions
[10,11]. Moreover, the presence of coronary artery calci-
fication does not, in itself, predict the presence of ob-
structive atheroma. Calcification can, therefore, be used
as a surrogate marker of the extent of coronary athero-
sclerotic disease, rather than as a measure of luminal
stenosis [12].
Computed tomography coronary angiography
Major advances in scanning technology have led to the
establishment of noninvasive coronary angiography by
multidetector computed tomography (MDCT). This has a
very good agreement with invasive coronary angiography
[13,14] and intravascular ultrasound [13-16], with kappa
coefficient values of 0.75 for both. The resolution of mo-
dern scanners allows quantification of luminal stenoses as
well as identification of noncalcified ‘soft’ atherosclerotic
plaque [15]. Pooled analysis of over 800 patients indicates
a sensitivity of 89% (95% confidence intervals, 87 to 90%)
and specificity of 96% (95% confidence intervals, 96 to
97%) for 64-MDCT in comparison with invasive coronary
angiography [16]. The major strength is in the negative
predictive value of 98% (95% confidence intervals, 98 to
99%). The current evolution of scanning technology has
led to greater spatial and temporal resolution with lower
radiation doses (~2 to 3 mSv). This should translate into a
highly effective and safe imaging strategy, particularly for
the evaluation of stable patients with possible coronary
artery disease [17].
It is important to highlight that computed tomography
(CT) coronary angiography is primarily used to confirm
or refute the presence of coronary artery disease. The
diagnosis of angina pectoris due to coronary heart disease
primarily relies on two factors: (i) a history consistent with
angina pectoris, and (ii) the presence of obstructive coro-
nary artery disease. It should be realized that patients with
coronary heart disease may have nonanginal chest pain
and that patients with typical anginal chest pain may not
have coronary heart disease (see Table 1).
A health technology assessment including a compre-
hensive systematic review of 64-multidetector CTcoronary angiography highlighted several areas that
require further research, including (i) the usefulness of
MDCT coronary angiography in patients with suspected
coronary artery disease; (ii) the advantages of 256-
versus 64-MDCT coronary angiography; and (iii) the role
of MDCT to assess coronary artery plaque morphology
[18]. In addition, the National Institute of Clinical Excel-
lence (NICE) specifically called for research into the
clinical efficacy and cost-effectiveness of MDCT coro-
nary angiography compared with functional testing in
the diagnosis of angina [19].
Methods/design
Study design
This is an open parallel group prospective randomized
controlled trial, assessing the impact of CT on the diag-
nosis and management of patients attending a rapid
access chest pain clinic.
Study objectives
The purpose of a rapid access chest pain clinic is to
identify patients with symptoms of angina attributable to
coronary heart disease, in order to identify those who
would benefit from secondary prevention and anti-
anginal therapies. The standard approach is to document
a clinical history of angina pectoris and demonstrate
objective evidence of exercise-induced myocardial
ischaemia through exercise stress testing. We wish to
evaluate the added value of coronary artery calcium
scoring and CT coronary angiography in the assessment
of patients attending a rapid access chest pain clinic.
In the setting of a rapid access chest pain clinic, the
most important question that the patient has is whether
his or her chest pain is due to coronary heart disease.
The primary objective of the study, therefore, is to inves-
tigate whether the inclusion of coronary artery calcium
scoring and CT coronary angiography alters the propor-
tion of patients diagnosed with angina due to coronary
heart disease at 6 weeks.
The secondary objectives of the study are to ascertain
whether a coronary artery calcium score and CT coro-
nary angiogram influences the management of patients
with coronary heart disease or noncardiac causes of
chest pain. Patients’ concerns often relate to the chest
pain itself (symptoms), what causes their symptoms
(diagnosis), what further tests are required (investiga-
tions), what medication or procedures are recommended
(treatments) and what the impact will be on their future
health (long-term outcomes). We will also assess safety
and health economic outcomes. We will undertake long-
term follow of these patients to determine whether CT
assessments independently predict future risk, and
whether this leads to improved clinical outcomes
through better guided use of therapies.
Table 1 Categorization of patients based on presence the presence or absence of angina pectoris and coronary heart
disease
Coronary heart disease
Yes No
Angina pectoris Yes High-risk and cause of symptoms Low-risk and cause of symptoms unclear
No High-risk but either symptoms unrelated or atypical presentation Low-risk and other cause of symptoms likely
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The primary endpoint of the study will be the propor-
tion of patients diagnosed with angina pectoris secon-
dary to coronary heart disease at 6 weeks. The clinician
in charge of the patients’ care will assign the diagnosis
following either (a) analysis of the coronary artery cal-
cium score and CT coronary angiogram (intervention
group), or (b) standard care (conservative group).Secondary endpoints
The following secondary endpoints will be evaluated: (i)
the frequency and severity of chest pain symptoms at six
weeks and six months; (ii) the CT observed presence
and extent of coronary artery disease; (iii) the diagnosis
and severity of coronary heart disease; (iv) the accuracy
of CT coronary angiography compared with the gold-
standard of invasive coronary angiography in those who
receive both investigations; (v) the effect on investiga-
tions, unscheduled care and healthcare resource
utilization; and (vi) the effect on patient management,
including secondary prevention, anti-anginal therapy
(pharmacological therapy and coronary revasculariza-
tion), and treatment of noncardiac chest pain (such as
hiatus hernia).
The study has been primarily set up to assess a
patient-focused symptom outcome. However, alterations
in management may result in long-term benefits to
patients. Therefore long-term outcomes will be assessed,
including: (i) cardiovascular death or nonfatal myocar-
dial infarction; (ii) cardiovascular death; (iii) nonfatal
myocardial infarction (universal definition); (iv) cardio-
vascular death, nonfatal myocardial infarction or nonfa-
tal stroke; (v) nonfatal stroke; (vi) all causes of death;
(vii) coronary revascularization, percutaneous coronary
intervention or coronary artery bypass graft surgery;
(viii) hospitalization for chest pain, including acute cor-
onary syndromes and noncoronary chest pain; and (ix)
hospitalization for cardiovascular disease, including cor-
onary artery disease, cerebrovascular disease and peri-
pheral arterial disease.Patient population
Participants will be identified from patients attending
the rapid access chest pain clinic. We will recruit 4,138
patients, randomized 1:1 to standard care (n = 2,069) orstandard care with coronary calcium score and CT
coronary angiography (n = 2,069).
Inclusion criteria will be: (i) attendance at the rapid
access chest pain clinic and (ii) age over 18 years but less
than or equal to 75 years.
Exclusion criteria will be: (i) inability or unwillingness
to undergo CT scanning; (ii) exceeding the weight tole-
rance of scanner; (iii) known severe renal failure (serum
creatinine >200 μmol/l or estimated glomerular filtration
rate <30 ml/min); (iv) previous recruitment to the trial;
(v) major allergy to iodinated contrast agent; (vi) inabi-
lity to give informed consent; (vii) known pregnancy; or
(viii) acute coronary syndrome within 3 months.
Participant selection and enrolment
The trial is a pragmatic evaluation of the added value of
CT coronary angiography in a rapid access chest pain
clinic. Only patients attending the rapid access chest
pain clinic will be approached to participate. The inclu-
sion and exclusion criteria are broad and inclusive, and
should enable rapid identification of eligible patients
attending the clinic.
Patients will be given a patient information sheet on
arrival at the rapid access chest pain clinic. After con-
sultation, all eligible patients will be approached to enter
the trial by the attending clinician. Written informed
consent will be obtained from patients willing to partici-
pate in the study (Figure 1).
Randomization
Following recruitment, patients who agree to undergo
research evaluation will be randomized (1:1), either to no
additional scanning or to undergo further evaluation with
coronary calcium scoring and CT coronary angiography
within 14 days of clinic attendance and before invasive
coronary angiography or other cardiac investigations.
Randomization will be conducted using a web-based sys-
tem to ensure allocation concealment and will incorporate
minimization to ensure matching for age, sex, body mass
index (height and weight), diabetes mellitus, prior history
of coronary heart disease, atrial fibrillation and baseline
diagnosis of angina due to coronary heart disease.
Equipoise
Attending clinicians in the rapid access chest pain clinic
will not be permitted to investigate patients with CT
Figure 1 Rapid access chest pain clinic attendance, eligibility and recruitment. (CHD, coronary heart disease; CT, computed tomography;
ECG, electrocardiogram; HDL, high dependency lipoprotein).
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to receive the scan as part of the trial. During the course
of the trial, it is anticipated that CT coronary angio-
graphy may start to be introduced into routine clinical
practice within the rapid access chest pain clinic setting.
It will be important that loss of equipoise does not
prejudice the trial. This practice will, therefore, be dis-
couraged during the course of the trial. Where this is
not feasible, either the trial centre will be closed or all
patients will be approached to participate in the trial
but, where a patient is randomized to standard of care,they will be excluded from undergoing a CT coronary
angiogram and an alternative noninvasive test will be
selected. Equipoise will be monitored through data
collected on unrecruited patients.
Study assessments and data collection
Clinic assessment
All patients will undergo routine evaluation at the rapid
access chest pain clinic including, where appropriate,
symptom-limited exercise electrocardiography using the
standard Bruce protocol. Patients will be categorized as
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informed by the NICE guideline [20]. In general, high-
risk patients will be treated for coronary heart disease
and undergo invasive coronary angiography (10%), and
low-risk patients (10%) will be reassured and discharged.
Intermediate-risk patients (80%) will be treated and fur-
ther investigated at the discretion of the clinician. In all
cases, the diagnosis and agreed management strategy
will be documented at the end of the clinic attendance.
Cardiovascular risk will be calculated using pre-
viously established risk scores, such as the ASSIGN
and Framingham scores.
The study data sheet will be used in the rapid access
chest pain clinic to document patient history, exami-
nation and management plan for all patients (recruited
and unrecruited). This will be completed by the atten-
ding clinician or nurse. This will also include assessment
of eligibility. The study pro forma for all ineligible parti-
cipants and eligible unrecruited participants will be
retained in an anonymized form to provide detailed data
on these patients in comparison with the study partici-
pant population. All study pro formas (recruited and
unrecruited eligible and ineligible patients) and consent
forms (recruited participants) will be collated by the trial
manager and entered into the database.
Blood tests
If the participant has not had total cholesterol and HDL
(high-density lipoprotein) cholesterol levels measured
within the past three months, a blood test will be taken
at the rapid access chest pain clinic. If the total choles-
terol is above 7.0 mmol/l or the HDL is below 0.5
mmol/l, the primary care physician will be informed by
letter, as this may warrant treatment irrespective of the
patient’s 10-year cardiovascular risk.
In a sub-group of patients, a venous blood sample will be
obtained and stored for future assessment of biomarkers.
Computed tomography
Computed tomography scans will be performed using a
64, 128 or 320-multidetector scanner. Computed tomog-
raphy protocol optimizations will be performed at all sites
throughout the study, to optimize scanning parameters,
such as radiation dose and contrast administration.
Medication Before calcium scoring, patients with a
heart rate of greater than 60 beats/min and systolic
blood pressure >110 mmHg will receive rate-limiting
medication. If a participant’s heart rate is above 100
beats per minute despite rate-limiting medication, CT
coronary angiography will not be performed. A small
dose of oral diazepam may be prescribed for anxious
patients, to improve heart rate control. Sublingualglyceryl trinitrate will be administered immediately prior
to CT imaging.
Coronary artery calcium score Coronary calcium sco-
ring will be performed prior to coronary angiography.
Investigators blind to patient characteristics will conduct
off-line analyses using automated computerized software
programs that employ the Agatston scoring method [21]
using a threshold of 130 Hounsfield units [11]. The cal-
cium score percentile based on age and sex will be cal-
culated using coronary artery calcium score distributions
from the Multi-Ethnic Study of Atherosclerosis (MESA)
[22]. This will be performed using a web-based calculator,
available at http://www.mesa-nhlbi.org/Calcium/input.
aspx. For patients younger than 45, 45 years will be used
for the calculation of the calcium score percentile.
Computed tomography coronary angiography Coronary
angiography will be conducted during contrast enhance-
ment using pre-specified protocols (as recommended by
the scannermanufacturers) during a single breathholdwith
prospective electrocardiographic gating as appropriate.
Image assessment
All CT and invasive coronary angiograms will be
assessed by at least two trained observers. Angiograms
(CT and invasive) will be reviewed independently and
without prior knowledge of the alternate angiogram.
Where there is disagreement between paired observers
(but not modalities), angiograms will be reviewed and
classified by consensus. Angiograms will be reported
using the 15-segment model [23]. Significant stenosis
due to coronary artery disease will be defined as a ste-
nosis greater than 70% in one or more major epicardial
vessels or greater than 50% in the left main stem [20].
Luminal cross-sectional area stenoses will be classified
as normal (<10%), haemodynamically insignificant (10-
49%), intermediate (50-70%), significant (greater than or
equal to 70%) or total or subtotal occlusion (100%).
Definition of coronary artery disease
Coronary artery disease will be classified as: (a) obstruct-
ive coronary artery disease, atherosclerotic plaque
encompassing a luminal cross-sectional area of ≥70% in
at least one major epicardial vessel; (b) nonobstructive
coronary artery disease, either atherosclerotic plaque
encompassing a luminal cross-sectional area of <70%
but >10% in at least one major epicardial vessel, or a cal-
cium score >400 AU (Agatston units) or >90th percent-
ile for age and sex; or (c) minimal or no coronary artery
disease. Significant plaque burden is defined as athero-
sclerotic plaque causing >10% luminal cross-sectional
area stenosis.
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Computed tomography scans will be reported locally by
two trained observers (radiologist and cardiologist). The
CT report will also include recommendations for manage-
ment, including primary or secondary prevention. Treat-
ment of angina due to coronary heart disease will be at
the discretion of the responsible consultant. (Figures 2
and 3). For participants in the no-CT-scan group, the re-
sponsible consultant will be sent a letter detailing the
patient’s ASSIGN score.
Symptom outcomes
At baseline, 6 weeks and 6 months, chest pain will be
assessed by the UK version of the Seattle Angina Ques-
tionnaire (SAQ-UK) [24] and quality of life will be assessed
by the 12-Item Short Form Health Survey (SF-12W). The
standard (4-week) recall second version of the SF-12W will
be used (SF-12v2™). The SF-12 Physical Component Sum-
mary (PCS) and Mental Component Summary (MCS)
scores will be calculated, along with utility scores based
on the SF-6D algorithm.
Baseline questionnaires will be handed to the patient
at the end of the rapid access chest pain clinic consult-
ation. At 6 weeks and 6 months, questionnaires will be
posted to participants, with telephone follow-up for non-
responders after two mailings two weeks apart.
Diagnostic outcomes
The proportion of patients diagnosed with coronary
heart disease will be documented at baseline, after CT
(where appropriate), after 6 weeks and after 6 months.
This will be defined as (i) prior history of coronary heart
disease (previous documented acute myocardial infarc-
tion (universal definition), obstructive coronary heart
disease (≥70% luminal stenosis in at least one major epi-
cardial vessel on invasive coronary angiography) or pre-
vious coronary revascularization (percutaneous coronary
intervention or coronary artery bypass surgery)), (ii)
clinical diagnosis of angina pectoris due to coronary
heart disease, or (iii) obstructive or nonobstructive CT
diagnosis of coronary heart disease. The extent of coron-
ary heart disease will be determined by the number of
vessels affected (none, one, two or three vessels diseased
(≥70% luminal stenosis of a major epicardial vessel)) and
plaque load determined by CT coronary angiography.
The accuracy of the CT coronary angiography will be
determined by comparison with invasive coronary angio-
graphy (gold-standard) for the assessment of the number
of vessels affected. The extent of plaque burden cannot
be compared between the two modalities.
Investigation outcomes
Relevant investigations will be documented for each par-
ticipant at the baseline clinic attendance, after 6 weeksand after 6 months. This will include: an exercise elec-
trocardiographic stress test; nuclear medicine imaging -
myocardial perfusion imaging; stress echocardiography;
invasive coronary angiography; and noncardiac investi-
gations, for example, endoscopy.
This will be documented by the clinician in charge of
patient care in response to the CT coronary angiogram re-
port. Further information will be obtained from electronic
hospital records and patient surveys. Computed tomog-
raphy coronary angiography will be performed prior to
any invasive coronary angiogram, to facilitate a decision to
undertake or cancel this invasive investigation.
Treatment outcomes
All treatments will be documented at baseline, after CT
scan (where appropriate), and at 6 weeks and 6 months.
Documentation of current prescribed medications will
be obtained from patients, electronic hospital records or
general practitioners. This will include:
1. Secondary prevention. Prescription of drug therapy
for the prevention of cardiovascular events will be
documented; drugs listed will include aspirin,
clopidogrel, other anti-platelet agents, statins,
angiotensin-converting enzyme inhibitor therapy, and
beta-blockers.
2. Pharmacological anti-anginal therapy. Prescription
of drug therapy (drug, class, dose) for the alleviation
of angina pectoris will be documented; this will
include beta-blockades, calcium antagonists, nitrates,
nicorandil, and ivabradine.
3. Coronary revascularization. The use of percutaneous
coronary intervention and coronary artery bypass
surgery will be documented at 6 weeks and 6 months.
Long-term outcomes
Annual hospitalizations for chest pain episodes, acute cor-
onary syndromes, coronary revascularization procedures,
cerebrovascular disease and peripheral vascular disease
will be recorded from the Information and Statistics Di-
vision of NHS Scotland, and deaths from the Central
Registry Office, Scotland for up to 10 years following trial
enrolment. Where possible, events will be corroborated by
electronic hospital records and case note review.
Diagnosis and management documentation
The CT scan report will include a section requesting the
documentation of any changes in the diagnosis, investi-
gation and treatment of the participant. The chest pain
clinic nurse or responsible consultant will complete this
pro forma and return it to the trial manager.
At 6 months, trial and data manager will document
changes in patient diagnosis, investigation and treatment
for all patients at 6 weeks and 6 months using the
Figure 2 Computed tomography coronary angiography results and diagnosis documentation. (CHD, coronary heart disease; CT, computed
tomography).
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ration, Cambridge, MA, USA), which is an electronic pa-
tient record system used by the National Health Service
(NHS) Lothian Health Board. This system is destined to
be adopted by other centres throughout Scotland. Where
appropriate, this will be supplemented by source docu-
ment review.Safety outcomes
Radiation dose
The main safety concerns relate to exposure to ionizing
radiation [25]. The dose-length product (DLP) will be
recorded and the effective radiation dose will becalculated using the conversion factor method. Age- and
sex-specific lifetime attributable risks of cancer will be
estimated using the Biological Effects of Ionizing Ra-
diation VII Phase 2 report [26]. All incident cancers
identified during the study will be recorded throughout
the follow-up phase of the trial.
Incidental findings
Incidental findings occur in 22 to 74% of CT scans of
the chest but only 1.7% of these are clinically significant
[27]. Nevertheless, any incidental findings may require
further investigations, involving exposure to ionizing ra-
diation. An incidental finding will be defined as an abnor-
mality identified on CT without antecedent clinical
Figure 3 Plan of investigation (CHD, coronary heart disease; CT, computed tomography; CVD, cardiovascular disease).
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of incidental findings will be documented at the time of
the initial CT coronary angiography and any further
investigations be documented by review of the partici-
pant’s medical records.Data analysis
The trial results will be reported in accordance with the
CONSORT guidelines and, where possible, the clinical
profile of unrecruited and ineligible patients will be
recorded.Statistical analysis
The trial statistician will supervise statistical analyses
performed by Edinburgh Clinical Trials Unit. A full sta-
tistical analysis plan will be written separately.Sample size
Previous studies have diagnosed angina pectoris in
27.0% of clinic attendees [6]. Whilst CT coronary angio-
graphy may reduce ‘false-positive’ diagnoses of angina;
this intervention is most likely to increase the diagnosis
of angina, given that current standard diagnostic
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coronary heart disease [6]. We believe that, to be clini-
cally useful, this intervention should increase the clinical
diagnosis of angina due to coronary heart disease in at
least 1 in 25 clinic attendees. For 80% power at a two-
sided P value of 0.05, we will need to recruit 2,069
patients per group to detect an absolute increase of 4.0%
in the diagnosis of angina.
Sample size: long-term outcome
Establishing the diagnosis of angina is an important as-
pect for the trial but ultimately it is the long-term pa-
tient outcome that is important; can patients’ chest pain
symptoms be resolved and their long-term outcome
improved? After 5 years of follow-up, we would antici-
pate a coronary event rate (coronary heart disease death
or acute coronary syndrome) of 13.1% for the total
population [6]. The study would have 80% power at a
two-sided P value of 0.05 to detect a decrease of 2.8% in
the 5-year event rate. This would also provide ~600
events and permit the exploration of up to 60 variables
[28] in evaluating the predictive value of established risk
factors and the novel risk factors of coronary artery cal-
cium score and CT coronary angiography.
Statistical analysis plan
Where appropriate, two main comparisons will be made:
(a) between the scanned and unscanned groups; and (b)
in the scanned group only, between the initial clinic as-
sessment and the final assessment following knowledge
of the CT scan. The primary analysis will be a compari-
son between the scanned and unscanned groups, of the
proportion of patients diagnosed with angina pectoris
secondary to coronary heart disease at 6 weeks. This
comparison will be performed using logistic regression,
adjusted for the variables in the minimization algorithm.
Health economic analysis
Health service costs will be assigned to the type and inten-
sity of resource use, measured by the number of diagnostic
and therapeutic procedures or interventions, medications,
hospital clinic attendances and hospitalization episodes
from randomization to 6 months of follow-up. Costs will
be attributed to the need for (i) additional invasive or non-
invasive imaging, (ii) drug therapy, (iii) coronary revascu-
larization, and (iv) hospitalization for chest pain.
Unit costs will reflect a mixture of approaches, includ-
ing activity-based analyses of resource consumption for
specific procedures or interventions alongside average
per diem in-patient costs calculated on a specialty-
specific basis using the Scottish Health Service Costs
system. Centre-specific costs for imaging and revascula-
rization procedures/interventions will be determined on
the basis of measured procedure duration and the unitcosts of these resources for cardiac catheterization la-
boratories and theatres. Local unit costs for labour, con-
sumables, overheads and depreciation will be obtained
from the finance department in each centre. The costs
of novel cardiac imaging modalities will be determined
using standard ‘bottom-up’ cost-accounting methods.
Costs of hospital admission and out-patient visits will be
measured using a ‘top-down’ costing method. These
costs will be estimated for each patient in the trial using
centre and specialty-specific average costs, which will
also be applied to subsequent in-patient episodes and
out-patient attendances beyond 6 months.
The SF-12W and SAQ-UK will be administered by self-
completed postal questionnaire at baseline and at 6
weeks and 6 months of follow-up. Standard scoring
algorithms will be used to calculate the SF-12W health
domain profile scales and physical and mental health
summary measures (PCS-12 and MCS-12, respectively).
The Short Form 6D (SF-6D), a single index preference-
based measure, will be calculated from the SF-12
responses using the Brazier algorithm. Missing hospital
cost and quality of life data will be analyzed using mul-
tiple imputation techniques.
Cost-effectiveness will be estimated using a prospective
within-trial analysis of treatment effects analyzed on an
intention-to-treat basis and a decision model of long-term
costs and health outcomes. Analysis will be performed
from the perspective of the health care system for resource
use and the individual patient for health outcomes. The
primary endpoint for the economic analysis will be incre-
mental cost-effectiveness ratios comparing the alternative
diagnostic strategies’ impact on health service use and
health related quality of life. The cost-effectiveness analysis
will be reported in terms of the incremental cost per
quality-adjusted life year (QALY) gained.
The SF-6D utility scores will be combined with sur-
vival times to enable estimation of QALYs for all rando-
mized patients. These will be estimated within-trial and
over the patients’ lifetime, by taking the sum of life years
obtained in each arm of the trial within the 6-month fol-
low-up period, modelling subsequent life expectancy and
then adjusting expected life-times for observed and
modelled SF-6D trajectories.
Information pertaining to resource use, cost, outcome
and cost-effectiveness will be reported as the mean per pa-
tient in each arm of the trial and the mean difference, with
appropriate measures of variance. Cost-effectiveness in
sub-groups will be estimated by applying any reduction in
overall relative risk or cost to different baseline absolute
risk groups. Cost-effectiveness acceptability curves and net
benefit statistics will also be reported.
Within-trial analyses will be integrated into a decision
model of long-term costs and health effects. The general
methods used will follow those defined as good practice
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lence (NICE). We propose to use a Monte-Carlo micro-
simulation model, similar to that recently used to assess
the cost-effectiveness of 64-MDCT coronary angiog-
raphy based triage for patients with low-risk chest pain
[29]. Base case analysis, using the intention-to-treat
results, and sensitivity analysis will be conducted by
varying key model parameters and critical assumptions
over plausible ranges and distributions. The decision
model will also permit the analysis of cost-effectiveness,
conditional on pre-specified coronary artery disease risk
strata [30] or other important patient characteristics.Study monitoring
The trial steering committee and trial management
group include representatives from the grant applicants
and trial management, as well as individuals not directly
involved in the trial. The study is assessing a diagnostic
intervention that is unlikely to lead to a major or safety-
event threshold before the end of trial recruitment.
Therefore, a data and safety monitoring committee will
not be convened.Discussion
The multicentre randomized controlled SCOT-HEART
trial will assess the added value of CT imaging in over
4,000 patients attending rapid access chest pain clinics.
This will define the most appropriate use of this emerging
technology in the setting of diagnosing and treating
patients with coronary heart disease and angina pectoris.
This study will also lay the foundation for future studies to
look at the potential prognostic value of this technology.
Current opinion suggests that the main utility of CT
coronary angiography lies with the diagnosis and ma-
nagement of patients at intermediate risk of coronary
heart disease [12,20] although recent evidence suggests
that it may have a role in the care of patients with sus-
pected acute coronary syndrome [31]. However, it could
have a role even in apparently high-risk patients with
stable symptoms, since CT may help identify patients
with ‘false-positive’ stress tests that could potentially
avoid invasive coronary angiography. Alternatively, it
may allow early identification of patients at high risk of
invasive coronary angiography (such as critical left main
stem stenosis), those with anomalous coronary anatomy,
or those for whom coronary revascularization is likely to
be necessary. In the latter scenario, this will facilitate
planning of invasive angiography and allow an interven-
tional cardiologist to undertake follow-on percutaneous
coronary intervention as required. This would poten-
tially avoid the need for recurrent invasive angiography
in situations where a noninterventional cardiologist per-
forms the diagnostic angiogram.For apparently low-risk patients, the use of CT coro-
nary angiography is controversial because of the high ra-
diation doses and low pre-test likelihood of disease. This
is a particular issue for younger patients and women
[25]. However, modern scanners have dramatically
reduced radiation exposure, whether because of the
increased speed of multidetector scanners that capture
the information in a single rotation or through the use
of pulse sequences with prospective electrocardiographic
gating. This may lead to better focused utilization of se-
condary preventative therapies in individuals who would
otherwise not receive treatment. There is also the added
value of imaging noncardiac structures that might be the
origin of the presenting chest pain. Finally, this proce-
dure is likely to provide more firm reassurance and po-
tentially more rapid resolution of symptoms in patients
anxious to establish whether they have significant coro-
nary heart disease.
Economic evaluation will assist policy makers in deci-
ding whether there is a cost-effective benefit associated
with MDCT scans. This is an expensive technology and
its healthcare value needs to be established. Potential
benefits of MDCT lie in (i) reducing further noninvasive
and invasive investigations, (ii) reducing symptoms and
improving quality of life through more focused therapy,
and (iii) improving long-term clinical outcomes. Thus,
measurement of cost-effectiveness requires estimation of
resource utilization, quality of life for all patients, and in
the subsequent follow-up study, event-free survival.
Without a comprehensive assessment of all patients
attending a rapid access chest pain clinic, the utility of
CT will remain undefined and open to question. We be-
lieve that this requires a randomized controlled trial to
evaluate this emerging and promising imaging techno-
logy in a comprehensive and pragmatic manner.
Trial status
The study has been approved by the South East Scotland
Research Ethics Committee. Recruitment is underway at
eight sites. At present, 1000 participants have been
recruited to the SCOT-HEART study.
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